Connect with us

International

Five Biopharmaceutical Stocks to Buy to Gain From Genetic Advances

Five biopharmaceutical stocks to buy to seize upon genetic advances still appear to have room for plenty of appreciation, according to seasoned market trackers who I asked to provide recommendations. The five biopharmaceutical stocks to buy to tap into…

Published

on

Five biopharmaceutical stocks to buy to seize upon genetic advances still appear to have room for plenty of appreciation, according to seasoned market trackers who I asked to provide recommendations.

The five biopharmaceutical stocks to buy to tap into genetic research inroads include companies that collectively are seeking to find effective treatments for amyotrophic lateral sclerosis (ALS) and muscular dystrophy, among others. As a former fundraiser for the Muscular Dystrophy Association (MDA) when I attended graduate school, I am among those who are hoping for long-sought treatments for that disease and many others that genetic research holds the promise to deliver.

“Biotechnology stocks have been doing well recently, and that’s likely to continue,” said Bob Carlson, leader of the Retirement Watch investment newsletter. “Companies continue to announce breakthroughs, and a number of biotech companies are going public.”

Pension fund and Retirement Watch leader Bob Carlson takes questions from Paul Dykewicz.

“The field of genomic medicine is one of the most promising new areas in medicine,” said Jim Woods, editor of Intelligence Report and Successful Investing. “Some of my favorites in the space are CRSP, BNGO and NTLA, but those aren’t the only ones.”

Source: Stock Rover. Click here to sign up for a free two-week trial.

Five Biopharmaceutical Stocks to Buy Include CRISPR Therapeutics

CRISPR Therapeutics (NASDAQ:CRSP), a Swiss-American biotechnology company headquartered in Zug, Switzerland, received an upgrade to “outperform” by Evercore ISI on May 13, along with a price target of $125 that the company has blown past in less than two months. The stock also roared beyond its $134 price target set by Citi when it boosted a rating on the stock to “neutral” from “sell” on June 11.

CRISPR Therapeutics is a biopharmaceutical company focused on developing what its management describes as “transformative, gene-based medicines” for serious diseases. It formed a partnership with Capsida Biotherapeutics Inc, a biotechnology company dedicated to developing breakthrough gene therapies using fully integrated adeno-associated virus (AAV) engineering. The two companies will collaborate to research, develop, manufacture and commercialize in vivo gene editing therapies that are delivered with engineered AAV vectors to treat familial amyotrophic lateral sclerosis (ALS) and Friedreich’s ataxia.

Partnership Propels One of the Five Biopharmaceutical Stocks to Buy

Under the agreement, CRISPR Therapeutics will lead research and development of the Friedreich’s ataxia program and perform gene-editing activities for both programs, while Capsida will spearhead research and development of the ALS program and conduct capsid engineering for both endeavors. Capsida’s high-throughput AAV engineering platform generates capsids designed to target specific tissue types and to limit transduction of tissues and cell types that are not relevant to the target disease in hopes of improving efficacy and safety.

CRISPR Therapeutics and Capsida each have the option to co-develop and co-commercialize the program that the other company leads. The companies would share equally all research, development and commercialization costs and profits of the collaboration.

Chart courtesy of www.StockCharts.com

Woods Chooses Three of the Five Biopharmaceutical Stocks to Buy

Woods wrote in June that CRSIPR announced positive data from clinical trials for CTX001, a potential one-time therapy under development with it and Boston-based Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) for patients suffering from transfusion-dependent beta thalassemia and severe sickle cell disease.

“Blood disease therapies and other debilitating diseases that can be treated and cured by genomic companies are the next phase of this profoundly promising medical technology,” Woods opined.

BioNano Genomics Inc. (NASDAQ:BNGO), of San Diego, California, announced on July 6 that it has achieved “significant progress” in China with the adoption of its Saphyr System for optical genome mapping (OGM) by WeHealth Shanghai, a provider of genome analysis services for reproductive health. The adoption was discussed at the Structural Variation Symposium in Shanghai, organized with support from the Shanghai Society of Genetics.

Chart courtesy of www.StockCharts.com

Multiple presentations were delivered on reproductive health at the symposium, with speakers highlighting a significant need and opportunity in China with approximately 16 million births annually. Dr. Xiangdong Kong, based at The First Affiliated Hospital of Zhengzhou University, reported using optical genome mapping for prenatal testing in families with a history of facioscapulohumeral muscular dystrophy (FSHD), a form of muscular dystrophy.

BioNano Genomics received a “buy” recommendation on June 16 from the New York-based BTIG investment firm, along with a $10 price target. That projection would mark a 52.0% increase from the company’s closing price of $6.58 on July 6.

Paul Dykewicz interviews seasoned stock picker and investment newsletter veteran Jim Woods.

Two Stock Pickers Agree on One of the Five Biopharmaceutical Stocks to Buy

Intellia Therapeutics Inc. (NASDAQ:NTLA), a Cambridge, Massachusetts-based biopharmaceutical company, is another recommendation of Woods but he is not the only one to like the stock. Another is New York-based money manager Hilary Kramer, who also hosts the weekly “Millionaire Maker” radio program.

“A lot of the genetic stocks are close to fully valued after the great news from Intellia Biotherapeutics Inc. (NASDAQ:NTLA) a few weeks ago,” said Kramer, who heads the GameChangers and Value Authority advisory services. “Yes, this technology has now been validated in human patients. We can rewrite the liver and other organs to remove genetic faults and, in theory, program tired tissue to rejuvenate itself. The hard part took years, but it’s over.”

Now, NTLA just needs to develop specific applications, Kramer said. The real risk and returns have already played out in the favor of shareholders with vision and long-term conviction, she added.

Chart courtesy of www.StockCharts.com

Five Biopharmaceutical Stocks to Buy Include One Kramer Recommended Years Ago

“The time to buy Crispr Therapeutics, for example, was three years ago, when I was recommending it at under $60,” Kramer said. “You can still make money buying it here, but the next double might take five to 10 years.”

The same reasoning applies to NTLA, where the good news is now baked into the value of the stock, Kramer said. However, other opportunities for further upside gains remain, she added.

Editas Medicine Is One of Five Biopharmaceutical Stocks to Buy

“Editas Medicine Inc. (NASDAQ:EDIT) has more room to run,” Kramer counseled. “Even if it only recovers its 52-week high, people who come in now can do quite well for themselves. The key is to keep your eyes on the frontier as technologies that felt like a dream years ago move inexorably toward commercialization.”

Chart courtesy of www.StockCharts.com

Right now, CRSP, NTLA and Cambridge, Massachusetts-based EDIT are near the horizon as five biopharmaceutical stocks to buy to capture genetic advances. But stocks such as Precision BioSciences Inc. (NASDAQ:DTIL), a Durham, North Carolina-based clinical stage biotechnology company that is developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS genome editing platform, are only now coming in on that far frontier.

“That’s where the long-term gains happen,” Kramer said.

For that reason, Kramer identified Precision BioSciences as her favorite genetic drug stock for the long run.

Chart courtesy of www.StockCharts.com

“That end of the industry provides the kind of experience a lot of investors want from biotech,” Kramer said.

Paul Dykewicz conducts a pre-COVID-19 interview with Hilary Kramer, whose premium advisory services include IPO Edge, 2-Day Trader, Turbo Trader and Inner Circle.

Five Biopharmaceutical Stocks to Buy as New Variants of COVID-19 Spread

The Delta variant of COVID-19 that has spread to almost every state in America is heightening concerns among health officials about budding spikes in cases. Genetic variants of SARS-CoV-2 have been emerging and circulating worldwide throughout the COVID-19 pandemic, according to the Centers for Disease Control and Prevention (CDC).

A variant has one or more mutations that differentiate it from other varieties in circulation. The Delta variant is expected to become the dominant coronavirus strain in the United States, the CDC director recently said. With only about 47.5%, or 157,636,088 people, in the U.S. population fully vaccinated, public health officials warn a resurgence of Covid-19 cases may occur this fall when many unvaccinated children are expected to go back to school.

Progress in COVID-19 vaccinations raises hope that new cases and deaths will be curtailed. As of July 6, 182,714,064 people, or 55.0% of the U.S. population, have received at least one dose. President Joe Biden is among the elected officials in the United States who are urging people in the country who are eligible for COVID-19 vaccinations to receive them.

The Food and Drug Administration (FDA) recently approved a third COVID-19 vaccine, manufactured by Johnson & Johnson (NYSE:JNJ), and that one only requires one rather than the two doses needed with the first two vaccine providers: Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA).

COVID-19 cases worldwide have hit 184,546,452 and caused 3,991,715 deaths, as of late on July 6, according to Johns Hopkins University. U.S. COVID-19 cases totaled 33,746,452 and have led to 605,905 deaths. America has the dreaded distinction as the country with the most COVID-19 cases and deaths.

The five biopharmaceutical stocks to buy in search of genetic advances give investors ways to pursue profits while helping to fund the development of new treatments. Increased COVID-19 vaccine availability, an improving economy and a recent $1.9 trillion federal stimulus package could lift the valuations of the five biopharmaceutical stocks to buy to even healthier levels as the companies achieve genetic research progress.

Paul Dykewicz, www.pauldykewicz.com, is an accomplished, award-winning journalist who has written for Dow Jones, the Wall Street JournalInvestor’s Business DailyUSA Today, the Journal of Commerce, Seeking Alpha, GuruFocus and other publications and websites. Paul, who can be followed on Twitter @PaulDykewicz, is the editor of StockInvestor.com and DividendInvestor.com, a writer for both websites and a columnist. He further is editorial director of Eagle Financial Publications in Washington, D.C., where he edits monthly investment newsletters, time-sensitive trading alerts, free e-letters and other investment reports. Paul previously served as business editor of Baltimore’s Daily Record newspaper. Paul also is the author of an inspirational book, “Holy Smokes! Golden Guidance from Notre Dame’s Championship Chaplain,” with a foreword by former national championship-winning football coach Lou Holtz. The book is great as a gift and is endorsed by Joe Montana, Joe Theismann, Ara Parseghian, “Rocket” Ismail, Reggie Brooks, Dick Vitale and many others. Call 202-677-4457 for special Father’s Day gift pricing!

The post Five Biopharmaceutical Stocks to Buy to Gain From Genetic Advances appeared first on Stock Investor.

Read More

Continue Reading

International

Analysts issue unexpected crude oil price forecast after surge

Here’s what a key investment firm says about the commodity.

Published

on

Oil is an asset defined by volatility.

U.S. crude prices stood above $60 a barrel in January 2020, just as the covid pandemic began. Three months later, prices briefly went negative, as the pandemic crushed demand.

By June 2022 the price rebounded all the way to $120, as fiscal and monetary stimulus boosted the economy. The price fell back to $80 in September 2022. Since then, it has bounced between about $65 and $90.

Over the past two months, the price has climbed 15% to $82 as of March 20.

Oil prices often trade in a roller-coaster fashion.

Bullish factors for oil prices

The move stems partly from indications that economic growth this year will be stronger than analysts expected.

Related: The Fed rate decision won't surprise markets. What happens next might

Vanguard has just raised its estimate for 2024 U.S. GDP growth to 2% from 0.5%.

Meanwhile, China’s factory output and retail sales exceeded forecasts in January and February. That could boost oil demand in the country, the world's No. 1 oil importer.

Also, drone strokes from Ukraine have knocked out some of Russia’s oil refinery capacity. Ukraine has hit at least nine major refineries this year, erasing an estimated 11% of Russia’s production capacity, according to Bloomberg.

“Russia is a gas station with an army, and we intend on destroying that gas station,” Francisco Serra-Martins, chief executive of drone manufacturer Terminal Autonomy, told the news service. Gasoline, of course, is one of the products made at refineries.

Speaking of gas, the recent surge of oil prices has sent it higher as well. The average national price for regular gas totaled $3.52 per gallon Wednesday, up 7% from a month ago, according to the American Automobile Association. And we’re nearing the peak driving season.

Another bullish factor for oil: Iraq said Monday that it’s cutting oil exports by 130,000 barrels per day in coming months. Iraq produced much more oil in January and February than its OPEC (Organization of Petroleum Exporting Countries) target.

Citigroup’s oil-price forecast

Yet, not everyone is bullish on oil going forward. Citigroup analysts see prices falling through next year, Dow Jones’s Oil Price Information Service (OPIS) reports.

More Economic Analysis:

The analysts note that supply is at risk in Israel, Iran, Iraq, Libya, and Venezuela. But Saudi Arabia, the UAE, Kuwait, and Russia could easily make up any shortfall.

Moreover, output should also rise this year and next in the U.S., Canada, Brazil, and Guyana, the analysts said. Meanwhile, global demand growth will decelerate, amid increased electric vehicle use and economic weakness.

Regarding refineries, the analysts see strong gains in capacity and capacity upgrades this year.

What if Donald Trump is elected president again? That “would likely be bearish for oil and gas," as Trump's policies could boost trade tension, crimping demand, they said.

The analysts made predictions for European oil prices, the world’s benchmark, which sat Wednesday at $86.

They forecast a 9% slide in the second quarter to $78, then a decline to $74 in the third quarter and $70 in the fourth quarter.

Next year should see a descent to $65 in the first quarter, $60 in the second and third, and finally $55 in the fourth, Citi said. That would leave the price 36% below current levels.

U.S. crude prices will trade $4 below European prices from the second quarter this year until the end of 2025, the analysts maintain.

Related: Veteran fund manager picks favorite stocks for 2024

Read More

Continue Reading

International

Disney remote jobs: the most magical WFH careers on earth?

Disney employs hundreds of thousands of employees at its theme parks and elsewhere, but the entertainment giant also offers opportunities for remote w…

Published

on

The Walt Disney Co. (DIS)  is a major entertainment and media company that operates amusement parks, produces movies and television shows, airs news and sports programs, and sells Mickey Mouse and Star Wars merchandise at its retail stores across the U.S.

While most of the jobs at the multinational entertainment conglomerate require working with people — such as at its theme parks, film-production facilities, cruise ships, or corporate offices — there are also opportunities for remote work at Disney. And while remote typically means working from home, with Disney, it could also mean working in a non-corporate office and being able to move from one location to another and conduct business outside normal working hours.

Related: Target remote jobs: What type of work and how much does it pay?

What remote jobs are available at Disney?

Many companies, including Disney, have called employees to return to the office for work in the wake of the COVID-19 pandemic, and the bulk of the company’s positions are forward-facing, meaning they involve meeting with clients and customers on a regular basis. 

Still, there are some jobs at the “most magical company on earth” that are listed as remote and don’t require frequent in-person interaction with people, including opportunities in data entry and sales.

While thousands work in forward-facing positions, such as greeting customers at Disney’s theme parks around the world, there are some positions with the Walt Disney Co. that allow work to be done remotely.

Orlando Sentinel/Getty Images

On Disney’s career website, there are limited positions available where the work is completely remote. One listing, for example, is for a “graphics interface coordinator covering sporting events.” This role involves working on nights, weekends, and holidays — times when corporate offices tend to be closed — and it may make sense for the company to hire people who can work from home or to travel and work in a location separate from the game venue.

Some of the senior roles that are shown on the website involve managers who can oversee remote teams, whether that be in sales or data. Sometimes, a supervisor overseeing staff who work outside corporate offices may be responsible for hiring freelancers who work remotely.

On the employment website Indeed, there are limited positions listed. A job listing for a manager in enterprise underwriting for a federal credit union indicates weekend duty, working outside of an 8 a.m. to 5 p.m. schedule, and being able to work in different locations. The listed annual salary range of $84,960 to $132,000, though, is well above the national annual average of around $50,000.

Internationally, Disney offers remote work in India, largely in the field of software development for its India-based streaming platform, Disney+ Hotstar.

The company also offers some hybrid schemes, which involve a mixture of in-office and remote work. For a mid-level animator position based in San Francisco, the role would involve being in the office and working from home occasionally.

How much do remote jobs at Disney pay?

Pay for remote jobs at Disney varies significantly based on location. A salary for a freelance artist in New York City, for example, may be higher than for the same job in Orlando, Florida. 

Disney lists actual salary ranges in some of its job postings. For example, the yearly pay for a California-based compensation manager who works with clients is $129,000 to $165,000.

In an online search for “remote jobs at Disney,” results range from $30 to $39 an hour, for data entry, or $28.50 to $38 an hour for social media customer support.

How can I apply for remote jobs at Disney?

You can look for remote jobs on Disney's career site, and type “remote” in the search field. Listings may also appear on career-data websites, including Indeed and Glassdoor.

How many employees does Disney have?

In 2023, Disney employed about 225,000 people globally, of which around 77% were full-time, 16% part-time, and 7% seasonal. The majority of the workers, around 167,000, were in the U.S.

Disney says that a significant number of its employees, including many of those who work at its theme parks, along with most writers, directors, actors, and production personnel, belong to unions. It’s not immediately known how many remote workers at the company, if any, are union members. 

Read More

Continue Reading

International

The Digest #194

Poor Charlie’s Almanack, Ben Graham, GAAP accounting, John Templeton, AI dystopia, Inflation, Bloomstran on Berkshire, Intuitive Surgical, The lessons…

Published

on

Poor Charlie’s Almanack

Poor Charlie’s Almanack: The Essential Wit and Wisdom of Charles T. Munger was first published in 2005 as a “coffee table” style book. It was beautifully presented but came with a high price tag. It was also heavy, somewhat unwieldy to read, and not very portable. The book’s format and price probably limited its reach. 

Stripe Press published a new edition of the book shortly after Mr. Munger died last year at the age of ninety-nine. Amazon and other vendors instantly sold all available inventory. After waiting for three months, I finally received my copy last week. 

Peter Kaufman is the editor of all editions of the book and I suspect that his main goal two decades ago was to honor Charlie Munger’s wisdom in a format that was not expected to “go viral.” In 2005, Charlie Munger was well known in the Berkshire Hathaway shareholder community and in the value investing world, but he was not as prominent as he became during his final decade. The clear purpose of the new edition is to disseminate his ideas as widely as possible. 

The new edition is abridged to reduce repetitive content and I will withhold judgment about the wisdom of this abridgment until I finish reading the book. Since the heart of the book is comprised of speeches given by Charlie Munger, there are definitely cases where the same ideas are presented again and again. 

Great books can be read many times while remaining highly relevant. I found this to be the case when I reread Charlie Munger’s Harvard School commencement address delivered in June 1986 when his youngest son was among the graduates. In the speech, Mr. Munger “inverts” the typical advice delivered in such speeches by explaining how the graduates should go about guaranteeing a life of failure and misery through time-tested strategies such as ingesting drugs and indulging in envy and resentment. 

I am not sure how many graduates were convinced by Charlie Munger on that early summer day, but I suspect that most of them remember the speech because it was so unconventional. In contrast, I have no recollection of the commencement addresses when I graduated from high school or college, or even who the speaker was.


Articles

A Memorial for Charlie Munger by John Harvey Taylor, March 12, 2024. This is a brief account of a recent memorial service for Charlie Munger at Harvard-Westlake School. “We learned Sunday that someone once asked if he knew how to play the piano. ‘I don’t know,’ he said. ‘I’ve never tried.’ Yet he tried and finished so much in his century. Imagine what he is making of eternity.” (Episcopal Diocese of Los Angeles)

Benjamin Graham: Big Moments on the Way to Big Earnings, March 2024. Ben Graham’s granddaughter reflects on the challenges Graham experienced when he applied for college. “Most graduating seniors make their college plans in advance, but Ben Graham had no money for tuition. All through the long days of arduous farm labor, my grandfather dreamed of winning a Pulitzer Scholarship.” (Beyond Ben Graham)

Graham’s “Unpopular Large Caps” Part 2: Thoughts on Diversification by John Huber, March 19, 2024. “I would segment these ideas into two groups: core operating investments and bargain assets. In the former, you want to be very selective in picking a relatively small number of companies you intend to own for the long term. In the latter, you’d want to think like the insurance underwriter, buying as many as you can to ensure that the law of large numbers is on your side.” (Base Hit Investing)

Warren Buffett Minds the GAAP by Donald E. Graham, March 13, 2024. “I have a challenge for the FASB and the SEC: If you believe today’s accounting rules present a clearer picture of Berkshire’s results, put it to a test. Ask Berkshire’s shareholders if they prefer the present method of reporting earnings over the status quo ante. I don’t believe a single informed shareholder would say so. The rule is confusing and uninformative.” (WSJ)

  • Berkshire Hathaway’s Distorted Quarterly Results, August 7, 2022. “Berkshire’s net income figure has been totally useless for analytical purposes since 2018. This is true on an annual basis and even more true on a quarterly basis.” (The Rational Walk)

Sir John Templeton: The Gentleman Bargain Hunter by Kingswell, March 12, 2024. “Templeton, who passed away in 2008, arrived on the investing scene with a series of uber-profitable contrarian bets in the early days of World War II — and continued to outwit Mr. Market with maddening consistency for the next several decades.” (Kingswell)

They Praised AI at SXSW—and the Audience Started Booing by Ted Gioia, March 19, 2024. Many recent innovations seem to have a dystopian aura. Apparently, this sentiment is not restricted to the usual luddites (old men shouting at clouds) but is shared by some of the attendees of SXSW. What seems cool to tech bros in Silicon Valley might not seem so cool to those outside tech culture. (The Honest Broker)

We Still Don’t Believe How Much Things Cost by Rachel Wolfe and Rachel Louise Ensign, March 12, 2024. People tend to focus on the aggregate amount of inflation over the past few years and interpreted transitory to mean that price spikes would reverse. Of course, politicians and economists only meant that the rate of inflation would decrease, not that prices would ever return to pre-pandemic levels. (WSJ)

My 2023 Apple Report Card by John Gruber, March 18, 2024. A solid report card overall from a widely read technology blog. (Daring Fireball)


Podcasts

Christopher Bloomstran on Buffett, Berkshire, Munger, and China, March 19, 2024. 1 hour, 1 minute. Video. Also be sure to check out the latest Semper Augustus client letter which has a lengthy section on Berkshire Hathaway. (Value After Hours)

Renaissance Technologies, March 18, 2024. 3 hours, 10 minutes. Notes“Renaissance Technologies is the best performing investment firm of all time. And yet no one at RenTec would consider themselves an ‘investor’, at least in any traditional sense of the word. It’d rather be more accurate to call them scientists — scientists who’ve discovered a system of math, computers and artificial intelligence that has evolved into the greatest money making machine the world has ever seen.” (Acquired)

Intuitive Surgical: Robotic Precision, March 20, 2024. 1 hour, 6 minutes. Transcript“Intuitive creates robotic products to assist minimally invasive surgeries. Its Da Vinci system is a pioneer in this area as it increases the efficiency & accuracy of surgery and reduces the burden on the surgeons themselves.” (Business Breakdowns)

The Lessons of History (Will & Ariel Durant), March 18, 2023. 53 minutes. Notes“In every age men have been dishonest and governments have been corrupt.” (Founders)

A Classicist Believes that Homer Directly Dictated the Iliad, and Was Also an Excellent Horseman, March 14, 2024. 53 minutes. “The Iliad is the world’s greatest epic poem—heroic battle and divine fate set against the Trojan War. Its beauty and profound bleakness are intensely moving, but great questions remain: Where, how, and when was it composed and why does it endure?” (History Unplugged)


Triumph of Achilles

Triumph of Achilles by Franz von Matsch, 1892 (public domain)

Copyright, Disclosures, and Privacy Information

Nothing in this article constitutes investment advice and all content is subject to the copyright and disclaimer policy of The Rational Walk LLC.  The Rational Walk is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.

Read More

Continue Reading

Trending